Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets.

Nature cancer·2026
Same author

Translational bottlenecks in blood-based proteomics.

EMBO molecular medicine·2026
Same author

VO: The Vaccine Ontology.

Scientific data·2026
Same author

A 15-layer multi-omics analysis of gastric cancer ecotypes provides therapeutic insights.

Cell reports. Medicine·2026
Same author

The 2025 Report on the Human Proteome from the HUPO Human Proteome Project.

Journal of proteome research·2026
Same author

Impact of COVID-19 non-pharmaceutical interventions on bacterial infections in children: an international electronic health record-based study.

BMJ public health·2025
Same journal

Correction to "Marine Scrubbers vs Low-Sulfur Fuels: A Comprehensive Well-To-Wake Life Cycle Assessment Supported by Measurements Aboard an Ocean-Going Vessel".

Environmental science & technology·2026
Same journal

Emissions and Cost Trade-Offs of Time-Matched Clean Electricity Procurement under Interannual Weather Variability: A Case Study of Hydrogen Production.

Environmental science & technology·2026
Same journal

Divergent Thermal Feedbacks of Urbanization and Greening Modulate the Urban Heat Island in 21st-Century China.

Environmental science & technology·2026
Same journal

Friction-Mediated Transfer of Low Molecular Weight Chemicals from Consumer Mats to Fabrics: Insights for Dermal Exposure.

Environmental science & technology·2026
Same journal

Molecular Drivers of Contrasting Photoreactivity in Extracellular versus Intracellular Organic Matter from Chlorophyta and Cyanobacteria.

Environmental science & technology·2026
Same journal

Effective Precipitate Cleaning with a Reversible Flow Cell Sustains Stable Energy Intensity for Oceanic CO<sub>2</sub> Removal.

Environmental science & technology·2026
See all related articles

Related Experiment Video

Updated: May 25, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Ratcheting up cancer potency estimates.

Edmund A C Crouch1, Gilbert S Omenn

  • 1Cambridge Environmental, Inc, 58 Charles Street, Cambridge, Massachusetts 02141, United States. crouch@CambridgeEnvironmental.com

Environmental Science & Technology
|February 3, 2012
PubMed
Summary
This summary is machine-generated.

Cancer risk assessment in the U.S. uses rodent bioassay data, potentially overestimating human potency. Performing more bioassays may paradoxically increase these estimates, creating a counter-incentive for further research.

More Related Videos

Irradiator Commissioning and Dosimetry for Assessment of LQ &alpha; and &beta; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Analytical Determination of Mitochondrial Function of Excised Solid Tumor Homogenates
11:32

Analytical Determination of Mitochondrial Function of Excised Solid Tumor Homogenates

Published on: August 6, 2021

Related Experiment Videos

Last Updated: May 25, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ &alpha; and &beta; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Analytical Determination of Mitochondrial Function of Excised Solid Tumor Homogenates
11:32

Analytical Determination of Mitochondrial Function of Excised Solid Tumor Homogenates

Published on: August 6, 2021

Area of Science:

  • Toxicology
  • Risk Assessment
  • Environmental Health

Background:

  • Current U.S. cancer risk assessment relies on rodent bioassay data for human potency estimation.
  • The selection process often favors the highest extrapolated result from the most sensitive species or strain.
  • This method results in an upper-bound estimate, akin to an extreme value statistic.

Purpose of the Study:

  • To quantify the effect of additional bioassay data on cancer potency estimates.
  • To evaluate the impact of current risk assessment paradigms on incentives for further research.

Main Methods:

  • Analysis of a large dataset of collected rodent bioassay results.
  • Calculation of cancer potency estimates based on existing methodologies.
  • Statistical evaluation of the impact of additional data points on potency values.

Main Results:

  • Additional bioassay information consistently leads to equal or larger cancer potency estimates.
  • The current approach generates an upper-bound estimate that can be inflated by further testing.
  • This effect creates a disincentive for conducting additional bioassays.

Conclusions:

  • The methodology for cancer potency estimation may inadvertently inflate risk values with more data.
  • This inflation acts as a counter-incentive, discouraging further essential toxicological research.
  • Revising the risk assessment paradigm could encourage more comprehensive bioassay studies.